Engineering Intern
About the job
- Currently working toward a bachelor's or master's degree in Biomedical Engineering, Mechanical Engineering, Electrical Engineering, Industrial Engineering, Materials Science and Engineering, Computer Engineering, or a related engineering discipline, with an anticipated graduation date of Winter 2027, Spring 2028, Winter 2028, or Spring 2029.
- Currently authorized to work in the United States without requiring employment sponsorship now or in the future.
- Must reside in the United States for the duration of the internship.
- Must work on-site at least four days per week and participate full time for 40 hours per week.
- For baccalaureate degrees earned outside the United States, the degree must satisfy the requirements of 8 C.F.R. § 214.2(h)(4)(iii)(A).
- Support design, development, analysis, and testing of engineering solutions during research and product development phases.
- Contribute to system integration, verification, validation, risk analysis, and data-driven evaluation efforts.
- Support safety testing, regulatory compliance, and transfer of products from development into manufacturing.
- Design and support manufacturing processes, procedures, and production layouts for assemblies, equipment, machining, and material handling.
- Provide technical and sustaining engineering support within manufacturing environments, including equipment and process improvements.
- Contribute to continuous improvement efforts focused on quality, efficiency, and production yield.
- Develop, apply, and maintain quality standards and protocols for materials, components, and finished products.
- Collaborate with engineering, manufacturing, and supplier teams to support quality requirements and compliance.
- Support reliability studies, data analysis, and evaluation of design or test methods to achieve product reliability targets.
- Prior experience in engineering design, testing, manufacturing, quality, data analysis, or product development through internships, academic projects, research, laboratory work, or relevant work experience.
- Experience with engineering software, programming, computer-aided design, data analysis, or laboratory equipment.
- Experience creating technical documentation, laboratory reports, project summaries, test reports, or engineering presentations.
- Minimum 3.0 cumulative GPA on a 4.0 scale.
- Flexibility in geographic location.
About the company
Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Fridley, Minnesota
Founded
1949
Get referred to Medtronic
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 1, 2026 Q1 FY27 revenue rose 13.7%; guidance increased to 7.25%-7.75%.
- Cardiac Ablation Solutions grew 88% in Q1 FY27, validating Medtronic's fastest-growth platform.
- September 14, 2026 exchange offer advances MiniMed separation and unlocks capital allocation flexibility.
What critics are saying
- August 4, 2026 jury awarded $88 million over Covidien hernia mesh; thousands remain pending.
- February 5, 2026 jury found Medtronic owed $382 million over LigaSure antitrust bundling.
- FDA's July 2026 Harmony DCS recall and 2025 embolization recall expose recurring quality failures.
What makes Medtronic unique
- Hugo plus Cornerstone Sentire gives Medtronic two robotic surgery platforms outside the U.S.
- Affera Prism-2 and PulseSelect extend a differentiated, integrated cardiac ablation stack.
- MiniMed separation simplifies Medtronic into higher-margin franchises after the March 2026 IPO.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Program
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Medtronic has received FDA clearance and CE Mark for its Affera Prism-2 Mapping Software, expanding cardiac mapping capabilities for heart rhythm disorder procedures. The software creates detailed three-dimensional maps of the heart's electrical activity and uses magnetic and impedance-based tracking to display catheter locations, enabling procedures with minimal X-ray imaging. The company also obtained CE Mark for its PulseSelect ProxBox Adapter with Proximity Indicator software, which provides real-time feedback to help physicians assess catheter proximity to targeted heart tissue before energy delivery. The PulseSelect pulsed field ablation system was the first FDA-approved PFA catheter and is currently used in over 60 countries. These regulatory milestones advance Medtronic's integrated cardiac ablation portfolio, combining catheters, hardware and software to support precision during ablation procedures.
GE HealthCare appoints Rodolphe Katra as Chief AI Officer. September 29, 2026 Former Medtronic AI lead Rodolphe Katra joins GE HealthCare as Global Chief AI Officer as the company looks to build on its medical AI leadership GE HealthCare has appointed Rodolphe Katra as its new Global Chief AI Officer, as the medical technology company looks to expand its use of AI across devices, software and healthcare data. Rodolphe joins from Medtronic, where he served as Chief AI Officer for the past three years. Following in the footsteps of GE HealthCare's former AI chief Parminder Bhatia, who left the company in July 2026, Rodolphe will report to Global Chief Science and Technology Officer Taha Kass-Hout. The appointment comes as GE HealthCare seeks to build on a sizeable portfolio of AI-enabled medical devices. According to CEO Peter Arduini, the company has 134 AI-enabled medical devices authorised for medical use by the US Food and Drug Administration (FDA) - more than any other medtech company. Welcoming Rodolphe to the role on LinkedIn, Peter writes: "Working closely with our segment teams, Rodolphe will help us take our AI strategy to the next level - connecting devices, software and data to deliver better insights, more longitudinal understanding and more precise care." "At GE HealthCare, our goal is simple: build AI-enabled solutions that are making a difference for patients, clinicians and health systems. That's how we deliver growth and long-term value," he adds. "Rodolphe will help us take our AI strategy to the next level - connecting devices, software and data to deliver better insights, more longitudinal understanding and more precise care. " Peter ArduiniCEO of GE HealthCare From Medtronic to GE HealthCare. Rodolphe brings 25 years of experience across the industry and, most recently, more than a decade at Medtronic, where he held several leadership positions spanning research and development and technology. As Medtronic's Chief AI Officer, he led the creation of the company's first enterprise-wide AI Centre of Excellence, alongside developing AI governance frameworks and an enterprise AI strategy. He also oversaw the scaling of AI adoption across Medtronic's 15 business units, operating across more than 160 countries, while leading initiatives spanning enterprise AI, digital health and advanced analytics. Within Medtronic's Cardiac Rhythm business, which has more than US$6bn in revenue, Rodolphe also supported the use of AI and digital technologies to modernise operations, expand connected care and accelerate clinical innovation. Commenting on his appointment at GE HealthCare on LinkedIn, Rodolphe writes: "GE HealthCare is a storied company with a remarkable legacy of innovation, including leading the industry in FDA AI authorisations. "It's a privilege to join at such a pivotal moment for AI in healthcare, and to help take this work to the next level - connecting devices, software, and data to deliver better insights and more precise care for clinicians and patients." GE HealthCare: AI at a glance * 134 FDA authorisations - GE HealthCare says it has more AI-enabled medical device authorisations than any other medtech company. * Five years at the top - The company has ranked first on the FDA's AI-enabled medical device list for five consecutive years. * 200+ target - GE HealthCare has set a goal of securing more than 200 AI-enabled device authorisations by 2028. * AI across the care pathway - GE HealthCare's strategy combines smart devices, software, cloud and AI to support diagnosis, treatment and hospital operations, with recent work spanning radiation therapy and generative AI. Building on a long-standing AI strategy. GE HealthCare has ranked first for the number of FDA-authorised AI-enabled medical devices for five consecutive years, according to the company. Its AI strategy spans medical imaging, clinical workflows and operational applications, with the company increasingly exploring how AI can connect data and systems across the patient journey. That strategy was highlighted on 23 September 2026, when GE HealthCare announced a partnership with Boston, Massachusetts-based Mass General Brigham to explore the use of generative AI in radiation therapy. The collaboration will focus on helping radiation oncology teams bring together and interpret information needed to plan and deliver cancer treatment, which can currently be distributed across multiple systems. The partners plan to develop a generative AI tool that could be integrated with GE HealthCare's Intelligent Radiation Therapy (iRT) software. The platform is designed to support radiation therapy workflows by connecting tools, coordinating activities and reducing manual handoffs between different stages of care. The aim is to give clinical teams faster access to relevant information while helping patients move more efficiently from diagnosis towards treatment. Illustrating the velocity of GE HealthCare's AI launches, the company also launched CareIntellect for Operations on 15 September 2026, an AI-enabled software-as-a-service application designed to help healthcare organisations anticipate operational pressures. The platform can forecast potential capacity constraints up to 72 hours in advance by analysing patient and operational data, including bed availability, staffing levels and other hospital activity. Rodolphe's appointment adds a new layer of enterprise AI leadership as the company seeks to connect these technologies more closely across its portfolio. GE HealthCare - key partners. CEO: Jensen Huang | HQ: Santa Clara, California, US NVIDIA and GE HealthCare have a long-standing technology partnership focused on applying AI to medical imaging. Their collaboration has expanded into autonomous imaging, including X-ray and ultrasound, with NVIDIA's computing infrastructure supporting GE HealthCare's development of AI-enabled technologies. The relationship is particularly relevant to GE HealthCare's broader strategy of integrating AI into medical devices and clinical workflows. Mass General Brigham CEO: Anne Klibanski | HQ: Boston, Massachusetts, US Mass General Brigham and GE HealthCare have collaborated on healthcare AI and clinical research for several years. Their latest work explores generative AI for radiation oncology, with the aim of bringing together structured clinical data and unstructured information from multiple systems. The partnership builds on technology developed at Massachusetts General Hospital that became part of GE HealthCare's Intelligent Radiation Therapy solution. Mayo Clinic CEO: Gianrico Farrugia | HQ: Rochester, Minnesota, US GE HealthCare and Mayo Clinic have developed a strategic research relationship spanning medical imaging, AI, theranostics and radiation therapy. Their GEMINI-RT initiative focuses on integrating imaging, AI and patient monitoring to advance personalised radiation treatment. A further 2026 collaboration is exploring data-informed approaches to personalise radioligand therapy for patients with advanced prostate cancer. Company Portals
Medtronic (MDT): Q1 beat sparks target hikes, but Wall Street splits on re-rating case. Published September 23, 2026 at 2:08 pm EDT Medtronic plc (NYSE:MDT) drew a broad round of price-target increases after its fiscal 2027 first-quarter results, but Wall Street remains divided over whether accelerating growth can support a meaningful re-rating of the stock. Bull case: growth is broadening. Mizuho raised its target to $115 from $100 and maintained Outperform after Medtronic plc (NYSE:MDT) reported 13.7% organic revenue growth. Analyst Anthony Petrone highlighted roughly 7% organic growth across cardiovascular products, with Cardiac Ablation Solutions and new products driving upside. BofA also raised its target to $110 from $95 with Buy, saying growth drivers are emerging across nearly every business outside CAS. Wells Fargo increased its target to $104 from $102 with Overweight, pointing to the Q1 beat, CAS strength, and potential upside to fiscal 2027 guidance. The results gave those views additional support. The quarter included an extra fiscal week, which Medtronic estimated contributed about $570 million to revenue. Management subsequently raised its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from 6.75%-7.25%. CAS remained the standout, with revenue up 88%, while CRM, Pelvic Health and diabetes each grew 15%. Management expects CAS to grow more than 2.5 times its market in fiscal 2027. Bear case: growth may not yet merit a re-rating. The more cautious analysts also raised their targets, but their ratings show the remaining debate. Deutsche Bank lifted its target to $92 from $78 with Hold, Truist moved to $99 from $86 with Hold, and Stifel raised its target to $95 from $80 with Hold. Baird raised its target to $100 from $91 with Neutral, acknowledging the impressive growth acceleration but remaining less convinced that Medtronic plc (NYSE:MDT) deserves a higher valuation multiple. BTIG, meanwhile, raised its target to $100 from $91 with Buy but flagged questions around the durability of Hugo following Medtronic's $700 million investment in Cornerstone Robotics. Medtronic plc (NYSE:MDT) is also reinvesting part of its revenue upside into commercial acceleration and M&A. The Cornerstone investment creates foregone interest, while management has increased acquisitions and investments significantly over the past year. Hedge funds add as short interest falls. The institutional picture moved favorably in Q2. First Eagle Investment Management increased its stake 38% to 13.78 million shares, Arrowstreet Capital raised its position 177% to 12.89 million, Citadel added 447% to 5.37 million, D.E. Shaw increased 392% to 4.40 million, and AQR raised its position 103% to 3.30 million. Short interest fell to 12.13 million shares as of August 31 from 18.12 million a month earlier, a decline of about 33%. Short interest represented 0.95% of shares outstanding, with a 1.74-day short ratio. Valuation is the next test. Medtronic plc (NYSE:MDT) traded at a forward P/E of 15.1 as of September 22. The question for Wall Street is whether broader growth can persist beyond CAS and support that valuation. The December 10-11 Investor Day could provide the next major update on the company's longer-term growth trajectory.
How India's PLI scheme is shaping real jobs in 2026. Discover which sectors the PLI scheme truly fuels, the roles emerging today, and actionable steps to land those jobs. Introduction. India's Production-Linked Incentive (PLI) scheme has become the backbone of the country's industrial revival. While headlines often tout trillion-rupee investments, job-seekers wonder: what roles are actually being created?* This post breaks down the sectors where PLI incentives are translating into concrete employment, illustrates real-world examples, and gives you a roadmap to tap into these opportunities. 1. Manufacturing gets a talent boost. The original PLI focus - electronics, telecom equipment, and automotive components - has moved beyond capital spending to human capital. * - Electronics assembly hubs such as Foxconn's* new plant in Tamil Nadu now employ 1,800 line-workers, quality engineers, and supply-chain analysts. * - EV battery manufacturers like Exide Industries* and Tata Power* have expanded their R&D teams, hiring 250 battery chemists, data scientists, and safety engineers in the past year. * - White-goods PLI has spurred LG Innova* to open a smart-appliance factory in Gujarat, creating 400 roles ranging from CNC machinists to IoT software testers. What this means for you: The demand is not just for manual labor; firms need technical specialists who can manage advanced automation, quality control, and digital twins. Upskilling in PLC programming, robotics, and data analytics can make you a prime candidate. 2. Renewable Energy & Green manufacturing. In 2026, the PLI extension for solar PV modules and wind turbine components is delivering jobs that align with India's climate goals. * - Adani Green* commissioned a solar-cell line in Madhya Pradesh, hiring 300 production engineers and 150 maintenance technicians. * - Vestas India* opened a blade-fabrication unit in Karnataka, creating 200 roles for composite material experts and CAD designers. * - Ancillary services - logistics, warehouse management, and quality assurance - have added another 500 jobs across the supply chain. Action tip: If you have a background in mechanical engineering, materials science, or supply-chain logistics, consider short certification courses in solar PV design or wind turbine maintenance offered by NPTEL and the Indian Institute of Technology (IIT) platforms. 3. Pharma & medical devices - A hidden growth engine. The pharma PLI scheme, originally aimed at generic drug production, now fuels a surge in high-skill roles. * - Cipla* expanded its API (Active Pharmaceutical Ingredient) plant in Hyderabad, hiring 120 process engineers and 80 regulatory affairs specialists. * - Medtronic India* leveraged the medical-device PLI to set up a manufacturing unit for cardiac implants in Maharashtra, creating 250 positions for biomedical engineers and quality auditors. * - The ecosystem of contract research organizations (CROs) has grown, adding 400 jobs for clinical data managers and biostatisticians. Takeaway: Regulatory knowledge (USFDA, CDSCO) and expertise in Good Manufacturing Practices (GMP) are premium skills. Enroll in a GMP certification or a short-term regulatory affairs program to stay competitive. 4. Defence & aerospace - The new frontier. The defence-manufacturing PLI, launched in 2024, is now delivering tangible employment outcomes. * - Bharat Electronics* set up a radar-system assembly line in Delhi, employing 180 electronics engineers and 70 system-integration specialists. * - Hindustan Aeronautics* expanded its UAV production in Pune, creating 220 roles for aerospace designers, test pilots, and avionics software developers. * - Supporting industries - metal-fabrication, precision machining, and cybersecurity - have added 300 indirect jobs. Practical step: Defence projects often require security clearances. Begin the clearance process early, and consider a short course in defence procurement offered by the Institute of Defence Studies and Analyses (IDSA). 5. Digital services embedded in physical goods. A less obvious but rapidly growing area is the convergence of digital services with PLI-enabled products. * - Samsung*'s smart-home appliance line integrates AI voice assistants. The company hired 150 AI-model trainers and 80 data-privacy analysts in Bangalore. * - Mahindra & Mahindra*'s electric tractors now come with telematics dashboards, creating demand for IoT firmware engineers and field data analysts. * - Start-ups like Ather Energy* are outsourcing software development to TCS* and Infosys*, adding 200 fresh graduate positions for full-stack developers. How to act: Strengthen your full-stack development or AI/ML skill set. Platforms like Growthmenti offer curated learning paths aligned with these emerging roles. 6. Skill-Mapping & immediate actions for job-seekers. Understanding the macro-trend is only half the battle. Here's a checklist you can implement today: * - Identify your target sector (e.g., EV batteries, solar PV, pharma). Use the Ministry of Commerce's PLI dashboard to see which states have active incentives. * - Map required skills - cross-reference job postings on Naukri, LinkedIn, and Indeed with the roles listed above. Note recurring keywords such as PLC programming*, GMP*, IoT*, or regulatory affairs*. * - Enroll in micro-credentials - pick one certification that fills the biggest gap (e.g., Robotics Process Automation* from IIT Bombay, Solar PV Design* from NPTEL). * - Network strategically - join sector-specific LinkedIn groups (e.g., India EV Manufacturing*), attend virtual webinars hosted by the Confederation of Indian Industry (CII), and reach out to alumni from companies hiring under PLI. * - Build a project portfolio - for technical roles, create a GitHub repo or a CAD showcase that mirrors a real-world problem (e.g., designing a low-cost solar inverter). * - Tailor your resume - highlight any experience with government incentives, compliance, or cost-optimization projects; these resonate strongly with PLI-driven employers. Conclusion. The PLI scheme is no longer a buzzword; it is a job-creation engine reshaping India's employment landscape across manufacturing, renewable energy, pharma, defence, and digital-embedded services. By aligning your skill set with the sectors that are actually hiring, you can ride the wave of growth in 2026 and beyond. Ready to act? Visit Growthmenti's career-path tool, upload your resume, and get a personalized roadmap to the PLI-driven roles that match your profile. Your next opportunity could be just a certification away.
Medtronic expands surgical Robotics portfolio in $700 million Cornerstone partnership. Published. September 21, 2026 Medtronic is making an approximately $700 million investment as part of a partnership with Cornerstone Robotics that will add the Sentire surgical system to its robotic-assisted surgery portfolio and give it distribution rights in select markets outside the U.S. Sentire will be distributed alongside Medtronic's Hugo robotic-assisted surgery system where Cornerstone's platform is approved, giving Medtronic a two-platform portfolio for multi-port robotic surgery. Global adoption of robotic-assisted surgery remains in the single digits, according to Medtronic. Hugo is already used in more than 35 countries across six continents, with total procedures expected to exceed 50,000 globally by the end of the company's fiscal year. Matt Anderson, Senior Vice President and President of Surgical at Medtronic, said surgeons, health systems and markets have "varying needs and preferences," driving the company's investment across robotic platforms and related technologies. Sentire received CE Mark approval in May 2026 for minimally invasive general, gynecologic, thoracic and urologic procedures and has market approval in China and Singapore. Its design includes an immersive console with dual-console capability. Cornerstone founder and CEO Samuel Au said physicians and patients would be the "greatest beneficiaries" as the partnership expands access. Medtronic plans to continue developing Hugo through software upgrades, real-time artificial intelligence, integrated stapling, expanded instrumentation and additional clinical indications.